- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Somerset Today
By the People, for the People
Legend Biotech Beats Q1 Earnings Estimates
The biopharmaceutical company reported $0.01 EPS, exceeding analysts' expectations of -$0.17 per share.
Published on Mar. 10, 2026
Got story updates? Submit your updates here. ›
Legend Biotech (NASDAQ:LEGN), a commercial-stage biopharmaceutical company specializing in chimeric antigen receptor T-cell (CAR-T) therapies, reported its first-quarter earnings results on Tuesday. The company posted earnings per share of $0.01, surpassing the consensus estimate of -$0.17 per share. However, Legend Biotech reported revenue of $306.30 million for the quarter, slightly below the expected $310.21 million.
Why it matters
Legend Biotech's better-than-expected earnings results demonstrate the company's progress in advancing its lead asset, ciltacabtagene autoleucel (Carvykti), a BCMA-directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma. The company's ability to exceed earnings estimates amid the ongoing development of its pipeline could be seen as a positive sign by investors.
The details
Legend Biotech reported a negative net margin of 26.37% and a negative return on equity of 24.47% for the quarter. The company's revenue of $306.30 million was slightly below the consensus estimate of $310.21 million. Legend Biotech is a global biopharmaceutical company with research and development operations in Shanghai, China, in addition to its headquarters in Somerset, New Jersey.
- Legend Biotech reported its first-quarter earnings results on Tuesday, March 10, 2026.
The players
Legend Biotech
A commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology.
The takeaway
Legend Biotech's better-than-expected earnings results demonstrate the company's progress in advancing its lead CAR-T therapy, Carvykti, for the treatment of relapsed or refractory multiple myeloma. The company's ability to exceed earnings estimates amid ongoing pipeline development could be seen as a positive sign for investors.
